Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2002 Nov;57(11):994–999. doi: 10.1136/thorax.57.11.994

Lung cancer • 1: Prevention of lung cancer

G Goodman 1
PMCID: PMC1746232  PMID: 12403886

Full Text

The Full Text of this article is available as a PDF (112.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahrendt S. A., Chow J. T., Xu L. H., Yang S. C., Eisenberger C. F., Esteller M., Herman J. G., Wu L., Decker P. A., Jen J. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst. 1999 Feb 17;91(4):332–339. doi: 10.1093/jnci/91.4.332. [DOI] [PubMed] [Google Scholar]
  2. Albanes D., Heinonen O. P., Taylor P. R., Virtamo J., Edwards B. K., Rautalahti M., Hartman A. M., Palmgren J., Freedman L. S., Haapakoski J. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst. 1996 Nov 6;88(21):1560–1570. doi: 10.1093/jnci/88.21.1560. [DOI] [PubMed] [Google Scholar]
  3. Belinsky S. A., Nikula K. J., Palmisano W. A., Michels R., Saccomanno G., Gabrielson E., Baylin S. B., Herman J. G. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891–11896. doi: 10.1073/pnas.95.20.11891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bennett W. P., Hussain S. P., Vahakangas K. H., Khan M. A., Shields P. G., Harris C. C. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol. 1999 Jan;187(1):8–18. doi: 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  5. Berger M. S., Gullick W. J., Greenfield C., Evans S., Addis B. J., Waterfield M. D. Epidermal growth factor receptors in lung tumours. J Pathol. 1987 Aug;152(4):297–307. doi: 10.1002/path.1711520408. [DOI] [PubMed] [Google Scholar]
  6. Bertram J. S., Kolonel L. N., Meyskens F. L., Jr Rationale and strategies for chemoprevention of cancer in humans. Cancer Res. 1987 Jun 1;47(11):3012–3031. [PubMed] [Google Scholar]
  7. Block G., Patterson B., Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer. 1992;18(1):1–29. doi: 10.1080/01635589209514201. [DOI] [PubMed] [Google Scholar]
  8. Brabender J., Danenberg K. D., Metzger R., Schneider P. M., Park J., Salonga D., Hölscher A. H., Danenberg P. V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res. 2001 Jul;7(7):1850–1855. [PubMed] [Google Scholar]
  9. Cardenas V. M., Thun M. J., Austin H., Lally C. A., Clark W. S., Greenberg R. S., Heath C. W., Jr Environmental tobacco smoke and lung cancer mortality in the American Cancer Society's Cancer Prevention Study. II. Cancer Causes Control. 1997 Jan;8(1):57–64. doi: 10.1023/a:1018483121625. [DOI] [PubMed] [Google Scholar]
  10. Cerny T., Barnes D. M., Hasleton P., Barber P. V., Healy K., Gullick W., Thatcher N. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer. 1986 Aug;54(2):265–269. doi: 10.1038/bjc.1986.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chiba I., Takahashi T., Nau M. M., D'Amico D., Curiel D. T., Mitsudomi T., Buchhagen D. L., Carbone D., Piantadosi S., Koga H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 1990 Oct;5(10):1603–1610. [PubMed] [Google Scholar]
  12. Chollat-Traquet C. Tobacco or health: a WHO programme. Eur J Cancer. 1992;28(2-3):311–315. doi: 10.1016/s0959-8049(05)80041-3. [DOI] [PubMed] [Google Scholar]
  13. Clark L. C., Combs G. F., Jr, Turnbull B. W., Slate E. H., Chalker D. K., Chow J., Davis L. S., Glover R. A., Graham G. F., Gross E. G. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996 Dec 25;276(24):1957–1963. [PubMed] [Google Scholar]
  14. Clinton S. K., Emenhiser C., Schwartz S. J., Bostwick D. G., Williams A. W., Moore B. J., Erdman J. W., Jr cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):823–833. [PubMed] [Google Scholar]
  15. Colditz G. A., Stampfer M. J., Willett W. C. Diet and lung cancer. A review of the epidemiologic evidence in humans. Arch Intern Med. 1987 Jan;147(1):157–160. doi: 10.1001/archinte.147.1.157. [DOI] [PubMed] [Google Scholar]
  16. Cole P., Rodu B. Declining cancer mortality in the United States. Cancer. 1996 Nov 15;78(10):2045–2048. doi: 10.1002/(sici)1097-0142(19961115)78:10<2045::aid-cncr3>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  17. Connett J. E., Kuller L. H., Kjelsberg M. O., Polk B. F., Collins G., Rider A., Hulley S. B. Relationship between carotenoids and cancer. The Multiple Risk Factor Intervention Trial (MRFIT) Study. Cancer. 1989 Jul 1;64(1):126–134. doi: 10.1002/1097-0142(19890701)64:1<126::aid-cncr2820640122>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  18. D'Amico D., Carbone D., Mitsudomi T., Nau M., Fedorko J., Russell E., Johnson B., Buchhagen D., Bodner S., Phelps R. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene. 1992 Feb;7(2):339–346. [PubMed] [Google Scholar]
  19. David-Beabes G. L., Lunn R. M., London S. J. No association between the XPD (Lys751G1n) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):911–912. [PubMed] [Google Scholar]
  20. Dragnev K. H., Rigas J. R., Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist. 2000;5(5):361–368. doi: 10.1634/theoncologist.5-5-361. [DOI] [PubMed] [Google Scholar]
  21. Eli Y., Przedecki F., Levin G., Kariv N., Raz A. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61(5):565–571. doi: 10.1016/s0006-2952(00)00578-5. [DOI] [PubMed] [Google Scholar]
  22. Frazier M. L., O'Donnell F. T., Kong S., Gu X., Campos I., Luthra R., Lynch P. M., Amos C. I. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res. 2001 Feb 15;61(4):1269–1271. [PubMed] [Google Scholar]
  23. Gazdar A. F. The molecular and cellular basis of human lung cancer. Anticancer Res. 1994 Jan-Feb;14(1B):261–267. [PubMed] [Google Scholar]
  24. Giardiello F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R., Offerhaus G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May 6;328(18):1313–1316. doi: 10.1056/NEJM199305063281805. [DOI] [PubMed] [Google Scholar]
  25. Gong Y. L., Koplan J. P., Feng W., Chen C. H., Zheng P., Harris J. R. Cigarette smoking in China. Prevalence, characteristics, and attitudes in Minhang District. JAMA. 1995 Oct 18;274(15):1232–1234. [PubMed] [Google Scholar]
  26. Goodman G. E. Cancer prevention: chemoprevention vs dietary modifications. Prev Med. 1993 Sep;22(5):689–692. doi: 10.1006/pmed.1993.1062. [DOI] [PubMed] [Google Scholar]
  27. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  28. Greenwald P. NCI cancer prevention and control research. Prev Med. 1993 Sep;22(5):642–660. doi: 10.1006/pmed.1993.1058. [DOI] [PubMed] [Google Scholar]
  29. Halpern M. T., Gillespie B. W., Warner K. E. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst. 1993 Mar 17;85(6):457–464. doi: 10.1093/jnci/85.6.457. [DOI] [PubMed] [Google Scholar]
  30. Harris C. C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993 Dec 24;262(5142):1980–1981. doi: 10.1126/science.8266092. [DOI] [PubMed] [Google Scholar]
  31. Hecht S. S. Chemoprevention of lung cancer by isothiocyanates. Adv Exp Med Biol. 1996;401:1–11. doi: 10.1007/978-1-4613-0399-2_1. [DOI] [PubMed] [Google Scholar]
  32. Heckbert S. R., Weiss N. S., Hornung S. K., Eaton D. L., Motulsky A. G. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst. 1992 Mar 18;84(6):414–422. doi: 10.1093/jnci/84.6.414. [DOI] [PubMed] [Google Scholar]
  33. Hendler F. J., Ozanne B. W. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest. 1984 Aug;74(2):647–651. doi: 10.1172/JCI111463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Herman J. G., Graff J. R., Myöhänen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821–9826. doi: 10.1073/pnas.93.18.9821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998 Sep 1;58(17):3761–3764. [PubMed] [Google Scholar]
  36. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  37. Hong W. K., Lippman S. M., Itri L. M., Karp D. D., Lee J. S., Byers R. M., Schantz S. P., Kramer A. M., Lotan R., Peters L. J. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990 Sep 20;323(12):795–801. doi: 10.1056/NEJM199009203231205. [DOI] [PubMed] [Google Scholar]
  38. Hosomi Y., Yokose T., Hirose Y., Nakajima R., Nagai K., Nishiwaki Y., Ochiai A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000 Nov;30(2):73–81. doi: 10.1016/s0169-5002(00)00132-x. [DOI] [PubMed] [Google Scholar]
  39. Hou S. M., Fält S., Yang K., Nyberg F., Pershagen G., Hemminki K., Lambert B. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls. Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):133–140. [PubMed] [Google Scholar]
  40. Humbert M., Delattre R. M., Cerrina J., Dartevelle P., Simonneau G., Emilie D. Serum neopterin after lung transplantation. Chest. 1993 Feb;103(2):449–454. doi: 10.1378/chest.103.2.449. [DOI] [PubMed] [Google Scholar]
  41. Hung W. C., Chang H. C., Pan M. R., Lee T. H., Chuang L. Y. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol Pharmacol. 2000 Dec;58(6):1398–1403. doi: 10.1124/mol.58.6.1398. [DOI] [PubMed] [Google Scholar]
  42. Isobe M., Emanuel B. S., Givol D., Oren M., Croce C. M. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986 Mar 6;320(6057):84–85. doi: 10.1038/320084a0. [DOI] [PubMed] [Google Scholar]
  43. Jemal Ahmedin, Thomas Andrea, Murray Taylor, Thun Michael. Cancer statistics, 2002. CA Cancer J Clin. 2002 Jan-Feb;52(1):23–47. doi: 10.3322/canjclin.52.1.23. [DOI] [PubMed] [Google Scholar]
  44. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  45. Kato S., Shields P. G., Caporaso N. E., Sugimura H., Trivers G. E., Tucker M. A., Trump B. F., Weston A., Harris C. C. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):515–518. [PubMed] [Google Scholar]
  46. Kelloff G. J., Crowell J. A., Boone C. W., Steele V. E., Lubet R. A., Greenwald P., Alberts D. S., Covey J. M., Doody L. A., Knapp G. G. Clinical development plan: 2-difluoromethylornithine (DFMO). J Cell Biochem Suppl. 1994;20:147–165. [PubMed] [Google Scholar]
  47. Kelloff G. J., Crowell J. A., Boone C. W., Steele V. E., Lubet R. A., Greenwald P., Alberts D. S., Covey J. M., Doody L. A., Knapp G. G. Clinical development plan: piroxicam. J Cell Biochem Suppl. 1994;20:219–230. [PubMed] [Google Scholar]
  48. Kelloff G. J., Crowell J. A., Boone C. W., Steele V. E., Lubet R. A., Greenwald P., Alberts D. S., Covey J. M., Doody L. A., Knapp G. G. Clinical development plan: sulindac. J Cell Biochem Suppl. 1994;20:240–251. [PubMed] [Google Scholar]
  49. Kelloff G. J., Hawk E. T., Crowell J. A., Boone C. W., Nayfield S. G., Perloff M., Steele V. E., Lubet R. A. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park) 1996 Oct;10(10):1471–1488. [PubMed] [Google Scholar]
  50. Kishimoto Y., Murakami Y., Shiraishi M., Hayashi K., Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 1992 Sep 1;52(17):4799–4804. [PubMed] [Google Scholar]
  51. Knekt P., Järvinen R., Seppänen R., Hellövaara M., Teppo L., Pukkala E., Aromaa A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol. 1997 Aug 1;146(3):223–230. doi: 10.1093/oxfordjournals.aje.a009257. [DOI] [PubMed] [Google Scholar]
  52. Koh H. K. An analysis of the successful 1992 Massachusetts tobacco tax initiative. Tob Control. 1996 Autumn;5(3):220–225. doi: 10.1136/tc.5.3.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Lee J. S., Lippman S. M., Benner S. E., Lee J. J., Ro J. Y., Lukeman J. M., Morice R. C., Peters E. J., Pang A. C., Fritsche H. A., Jr Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol. 1994 May;12(5):937–945. doi: 10.1200/JCO.1994.12.5.937. [DOI] [PubMed] [Google Scholar]
  54. Levi F., La Vecchia C., Lucchini F., Negri E. Cancer mortality in Europe, 1990-92. Eur J Cancer Prev. 1995 Oct;4(5):389–417. doi: 10.1097/00008469-199510000-00009. [DOI] [PubMed] [Google Scholar]
  55. Li D., Firozi P. F., Wang L. E., Bosken C. H., Spitz M. R., Hong W. K., Wei Q. Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case-control analysis. Cancer Res. 2001 Feb 15;61(4):1445–1450. [PubMed] [Google Scholar]
  56. Lippman S. M., Benner S. E., Hong W. K. Cancer chemoprevention. J Clin Oncol. 1994 Apr;12(4):851–873. doi: 10.1200/JCO.1994.12.4.851. [DOI] [PubMed] [Google Scholar]
  57. Lippman S. M., Lee J. J., Karp D. D., Vokes E. E., Benner S. E., Goodman G. E., Khuri F. R., Marks R., Winn R. J., Fry W. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001 Apr 18;93(8):605–618. doi: 10.1093/jnci/93.8.605. [DOI] [PubMed] [Google Scholar]
  58. Lonardo F., Rusch V., Langenfeld J., Dmitrovsky E., Klimstra D. S. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 1999 May 15;59(10):2470–2476. [PubMed] [Google Scholar]
  59. Lubin J. H., Blot W. J. Lung cancer and smoking cessation: patterns of risk. J Natl Cancer Inst. 1993 Mar 17;85(6):422–423. doi: 10.1093/jnci/85.6.422. [DOI] [PubMed] [Google Scholar]
  60. Mao L., Hruban R. H., Boyle J. O., Tockman M., Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 1994 Apr 1;54(7):1634–1637. [PubMed] [Google Scholar]
  61. Mao L., Lee J. S., Kurie J. M., Fan Y. H., Lippman S. M., Lee J. J., Ro J. Y., Broxson A., Yu R., Morice R. C. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst. 1997 Jun 18;89(12):857–862. doi: 10.1093/jnci/89.12.857. [DOI] [PubMed] [Google Scholar]
  62. Melamed M. R., Zaman M. B., Flehinger B. J., Martini N. Radiologically occult in situ and incipient invasive epidermoid lung cancer: detection by sputum cytology in a survey of asymptomatic cigarette smokers. Am J Surg Pathol. 1977 Mar;1(1):5–16. doi: 10.1097/00000478-197701010-00001. [DOI] [PubMed] [Google Scholar]
  63. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul;1(7):686–692. doi: 10.1038/nm0795-686. [DOI] [PubMed] [Google Scholar]
  64. Meyskens F. L., Jr, Emerson S. S., Pelot D., Meshkinpour H., Shassetz L. R., Einspahr J., Alberts D. S., Gerner E. W. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst. 1994 Aug 3;86(15):1122–1130. doi: 10.1093/jnci/86.15.1122. [DOI] [PubMed] [Google Scholar]
  65. Murray C. J., Lopez A. D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997 May 3;349(9061):1269–1276. doi: 10.1016/S0140-6736(96)07493-4. [DOI] [PubMed] [Google Scholar]
  66. Nakachi K., Imai K., Hayashi S., Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993 Jul 1;53(13):2994–2999. [PubMed] [Google Scholar]
  67. Nazar-Stewart V., Motulsky A. G., Eaton D. L., White E., Hornung S. K., Leng Z. T., Stapleton P., Weiss N. S. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res. 1993 May 15;53(10 Suppl):2313–2318. [PubMed] [Google Scholar]
  68. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  69. Nomura A. M., Stemmermann G. N., Heilbrun L. K., Salkeld R. M., Vuilleumier J. P. Serum vitamin levels and the risk of cancer of specific sites in men of Japanese ancestry in Hawaii. Cancer Res. 1985 May;45(5):2369–2372. [PubMed] [Google Scholar]
  70. Ohta M., Inoue H., Cotticelli M. G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996 Feb 23;84(4):587–597. doi: 10.1016/s0092-8674(00)81034-x. [DOI] [PubMed] [Google Scholar]
  71. Omenn G. S., Goodman G. E., Thornquist M. D., Balmes J., Cullen M. R., Glass A., Keogh J. P., Meyskens F. L., Jr, Valanis B., Williams J. H., Jr Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996 Nov 6;88(21):1550–1559. doi: 10.1093/jnci/88.21.1550. [DOI] [PubMed] [Google Scholar]
  72. Ono J., Auer G., Caspersson T., Nasiell M., Saito T., Konaka C., Kato H., Hayata Y. Reversibility of 20-methylcholanthrene-induced bronchial cell atypia in dogs. Cancer. 1984 Sep 15;54(6):1030–1037. doi: 10.1002/1097-0142(19840915)54:6<1030::aid-cncr2820540617>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  73. Ozanne B., Richards C. S., Hendler F., Burns D., Gusterson B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol. 1986 May;149(1):9–14. doi: 10.1002/path.1711490104. [DOI] [PubMed] [Google Scholar]
  74. Palmisano W. A., Divine K. K., Saccomanno G., Gilliland F. D., Baylin S. B., Herman J. G., Belinsky S. A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000 Nov 1;60(21):5954–5958. [PubMed] [Google Scholar]
  75. Papadimitrakopoulou V. A., Izzo J., Mao L., Keck J., Hamilton D., Shin D. M., El-Naggar A., den Hollander P., Liu D., Hittelman W. N. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res. 2001 Oct;7(10):3127–3134. [PubMed] [Google Scholar]
  76. Park Jae Yong, Lee Su Yeon, Jeon Hyo-Sung, Bae Nack Chun, Chae Sang Chul, Joo Soyoung, Kim Chang Ho, Park Jae-Ho, Kam Sin, Kim In San. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):23–27. [PubMed] [Google Scholar]
  77. Perera F. P. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst. 1996 Apr 17;88(8):496–509. doi: 10.1093/jnci/88.8.496. [DOI] [PubMed] [Google Scholar]
  78. Peto R., Lopez A. D., Boreham J., Thun M., Heath C., Jr, Doll R. Mortality from smoking worldwide. Br Med Bull. 1996 Jan;52(1):12–21. doi: 10.1093/oxfordjournals.bmb.a011519. [DOI] [PubMed] [Google Scholar]
  79. Ratnasinghe D., Yao S. X., Tangrea J. A., Qiao Y. L., Andersen M. R., Barrett M. J., Giffen C. A., Erozan Y., Tockman M. S., Taylor P. R. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):119–123. [PubMed] [Google Scholar]
  80. Risser N. L. Prevention of lung cancer: the key is to stop smoking. Semin Oncol Nurs. 1996 Nov;12(4):260–269. doi: 10.1016/s0749-2081(96)80024-6. [DOI] [PubMed] [Google Scholar]
  81. Rusch V., Klimstra D., Linkov I., Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res. 1995 Mar 15;55(6):1365–1372. [PubMed] [Google Scholar]
  82. Salgia R., Skarin A. T. Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar;16(3):1207–1217. doi: 10.1200/JCO.1998.16.3.1207. [DOI] [PubMed] [Google Scholar]
  83. Shapiro G. I., Park J. E., Edwards C. D., Mao L., Merlo A., Sidransky D., Ewen M. E., Rollins B. J. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 1995 Dec 15;55(24):6200–6209. [PubMed] [Google Scholar]
  84. Shen H., Spitz M. R., Wang L. E., Hong W. K., Wei Q. Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):397–401. [PubMed] [Google Scholar]
  85. Shopland D. R., Hartman A. M., Gibson J. T., Mueller M. D., Kessler L. G., Lynn W. R. Cigarette smoking among U.S. adults by state and region: estimates from the current population survey. J Natl Cancer Inst. 1996 Dec 4;88(23):1748–1758. doi: 10.1093/jnci/88.23.1748. [DOI] [PubMed] [Google Scholar]
  86. Soslow R. A., Dannenberg A. J., Rush D., Woerner B. M., Khan K. N., Masferrer J., Koki A. T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000 Dec 15;89(12):2637–2645. doi: 10.1002/1097-0142(20001215)89:12<2637::aid-cncr17>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  87. Spitz M. R., Bondy M. L. Genetic susceptibility to cancer. Cancer. 1993 Aug 1;72(3 Suppl):991–995. doi: 10.1002/1097-0142(19930801)72:3+<991::aid-cncr2820721307>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  88. Spitzer W. O., Lawrence V., Dales R., Hill G., Archer M. C., Clark P., Abenhaim L., Hardy J., Sampalis J., Pinfold S. P. Links between passive smoking and disease: a best-evidence synthesis. A report of the Working Group on Passive Smoking. Clin Invest Med. 1990 Feb;13(1):17–46. [PubMed] [Google Scholar]
  89. Sporn M. B., Dunlop N. M., Newton D. L., Smith J. M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976 May 1;35(6):1332–1338. [PubMed] [Google Scholar]
  90. Stahl W., Sies H. Lycopene: a biologically important carotenoid for humans? Arch Biochem Biophys. 1996 Dec 1;336(1):1–9. doi: 10.1006/abbi.1996.0525. [DOI] [PubMed] [Google Scholar]
  91. Stellman S. D., Takezaki T., Wang L., Chen Y., Citron M. L., Djordjevic M. V., Harlap S., Muscat J. E., Neugut A. I., Wynder E. L. Smoking and lung cancer risk in American and Japanese men: an international case-control study. Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1193–1199. [PubMed] [Google Scholar]
  92. Stoner G. D., Morse M. A. Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Lett. 1997 Mar 19;114(1-2):113–119. doi: 10.1016/s0304-3835(97)04639-9. [DOI] [PubMed] [Google Scholar]
  93. Stähelin H. B., Gey K. F., Eichholzer M., Lüdin E., Bernasconi F., Thurneysen J., Brubacher G. Plasma antioxidant vitamins and subsequent cancer mortality in the 12-year follow-up of the prospective Basel Study. Am J Epidemiol. 1991 Apr 15;133(8):766–775. doi: 10.1093/oxfordjournals.aje.a115955. [DOI] [PubMed] [Google Scholar]
  94. Swafford D. S., Middleton S. K., Palmisano W. A., Nikula K. J., Tesfaigzi J., Baylin S. B., Herman J. G., Belinsky S. A. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol. 1997 Mar;17(3):1366–1374. doi: 10.1128/mcb.17.3.1366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Takahashi T., Nau M. M., Chiba I., Birrer M. J., Rosenberg R. K., Vinocour M., Levitt M., Pass H., Gazdar A. F., Minna J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989 Oct 27;246(4929):491–494. doi: 10.1126/science.2554494. [DOI] [PubMed] [Google Scholar]
  96. Tammemagi M. C., McLaughlin J. R., Bull S. B. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):625–634. [PubMed] [Google Scholar]
  97. Topping D. C., Griesemer R. A., Nettesheim P. Quantitative assessment of generalized epithelial changes in tracheal mucosa following exposure to 7,12-dimethylbenz(a)anthracene. Cancer Res. 1979 Dec;39(12):4823–4828. [PubMed] [Google Scholar]
  98. Veale D., Ashcroft T., Marsh C., Gibson G. J., Harris A. L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 1987 May;55(5):513–516. doi: 10.1038/bjc.1987.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Virtamo J., Valkeila E., Alfthan G., Punsar S., Huttunen J. K., Karvonen M. J. Serum selenium and risk of cancer. A prospective follow-up of nine years. Cancer. 1987 Jul 15;60(2):145–148. doi: 10.1002/1097-0142(19870715)60:2<145::aid-cncr2820600203>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  100. Wald N. J., Nanchahal K., Thompson S. G., Cuckle H. S. Does breathing other people's tobacco smoke cause lung cancer? Br Med J (Clin Res Ed) 1986 Nov 8;293(6556):1217–1222. doi: 10.1136/bmj.293.6556.1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Wald N. J., Thompson S. G., Densem J. W., Boreham J., Bailey A. Serum beta-carotene and subsequent risk of cancer: results from the BUPA Study. Br J Cancer. 1988 Apr;57(4):428–433. doi: 10.1038/bjc.1988.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Watkins D. N., Lenzo J. C., Segal A., Garlepp M. J., Thompson P. J. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J. 1999 Aug;14(2):412–418. doi: 10.1034/j.1399-3003.1999.14b28.x. [DOI] [PubMed] [Google Scholar]
  103. Willett W. C., Polk B. F., Underwood B. A., Stampfer M. J., Pressel S., Rosner B., Taylor J. O., Schneider K., Hames C. G. Relation of serum vitamins A and E and carotenoids to the risk of cancer. N Engl J Med. 1984 Feb 16;310(7):430–434. doi: 10.1056/NEJM198402163100705. [DOI] [PubMed] [Google Scholar]
  104. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998 Nov 15;58(22):4997–5001. [PubMed] [Google Scholar]
  105. Woodson K., Stewart C., Barrett M., Bhat N. K., Virtamo J., Taylor P. R., Albanes D. Effect of vitamin intervention on the relationship between GSTM1, smoking, and lung cancer risk among male smokers. Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):965–970. [PubMed] [Google Scholar]
  106. Wu X., Shi H., Jiang H., Kemp B., Hong W. K., Delclos G. L., Spitz M. R. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis. 1997 May;18(5):967–973. doi: 10.1093/carcin/18.5.967. [DOI] [PubMed] [Google Scholar]
  107. Yoshida K., Hamajima N., Kozaki Ki, Saito H., Maeno K., Sugiura T., Ookuma K., Takahashi T. Association between the dopamine D2 receptor A2/A2 genotype and smoking behavior in the Japanese. Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):403–405. [PubMed] [Google Scholar]
  108. Zhou W., Thurston S. W., Liu G., Xu L. L., Miller D. P., Wain J. C., Lynch T. J., Su L., Christiani D. C. The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):461–466. [PubMed] [Google Scholar]
  109. Zhou Wei, Liu Geoffrey, Thurston Sally W., Xu Li Lian, Miller David P., Wain John C., Lynch Thomas J., Su Li, Christiani David C. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):15–21. [PubMed] [Google Scholar]
  110. Ziegler R. G., Colavito E. A., Hartge P., McAdams M. J., Schoenberg J. B., Mason T. J., Fraumeni J. F., Jr Importance of alpha-carotene, beta-carotene, and other phytochemicals in the etiology of lung cancer. J Natl Cancer Inst. 1996 May 1;88(9):612–615. doi: 10.1093/jnci/88.9.612. [DOI] [PubMed] [Google Scholar]
  111. van Zandwijk N., Dalesio O., Pastorino U., de Vries N., van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000 Jun 21;92(12):977–986. doi: 10.1093/jnci/92.12.977. [DOI] [PubMed] [Google Scholar]
  112. van den Brandt P. A., Goldbohm R. A., van 't Veer P., Bode P., Dorant E., Hermus R. J., Sturmans F. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Res. 1993 Oct 15;53(20):4860–4865. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES